289 related articles for article (PubMed ID: 30916493)
21. Myostatin inhibition induces muscle fibre hypertrophy prior to satellite cell activation.
Wang Q; McPherron AC
J Physiol; 2012 May; 590(9):2151-65. PubMed ID: 22393251
[TBL] [Abstract][Full Text] [Related]
22. Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein.
Li Q; Kumar R; Underwood K; O'Connor AE; Loveland KL; Seehra JS; Matzuk MM
Mol Hum Reprod; 2007 Sep; 13(9):675-83. PubMed ID: 17704537
[TBL] [Abstract][Full Text] [Related]
23. Soluble activin receptor type IIB decoy receptor differentially impacts murine osteogenesis imperfecta muscle function.
Jeong Y; Daghlas SA; Kahveci AS; Salamango D; Gentry BA; Brown M; Rector RS; Pearsall RS; Phillips CL
Muscle Nerve; 2018 Feb; 57(2):294-304. PubMed ID: 28555931
[TBL] [Abstract][Full Text] [Related]
24. Effects of the activin A-myostatin-follistatin system on aging bone and muscle progenitor cells.
Bowser M; Herberg S; Arounleut P; Shi X; Fulzele S; Hill WD; Isales CM; Hamrick MW
Exp Gerontol; 2013 Feb; 48(2):290-7. PubMed ID: 23178301
[TBL] [Abstract][Full Text] [Related]
25. Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators.
Souza TA; Chen X; Guo Y; Sava P; Zhang J; Hill JJ; Yaworsky PJ; Qiu Y
Mol Endocrinol; 2008 Dec; 22(12):2689-702. PubMed ID: 18927237
[TBL] [Abstract][Full Text] [Related]
26. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy.
Lach-Trifilieff E; Minetti GC; Sheppard K; Ibebunjo C; Feige JN; Hartmann S; Brachat S; Rivet H; Koelbing C; Morvan F; Hatakeyama S; Glass DJ
Mol Cell Biol; 2014 Feb; 34(4):606-18. PubMed ID: 24298022
[TBL] [Abstract][Full Text] [Related]
27. Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A.
Lee SJ; Lehar A; Liu Y; Ly CH; Pham QM; Michaud M; Rydzik R; Youngstrom DW; Shen MM; Kaartinen V; Germain-Lee EL; Rando TA
Proc Natl Acad Sci U S A; 2020 Dec; 117(49):30907-30917. PubMed ID: 33219121
[TBL] [Abstract][Full Text] [Related]
28. Activin type IIB receptor blockade does not limit adenosine triphosphate supply in mouse skeletal muscle in Vivo.
Béchir N; Pecchi É; Vilmen C; Bernard M; Bendahan D; Giannesini B
Muscle Nerve; 2018 Dec; 58(6):834-842. PubMed ID: 30025155
[TBL] [Abstract][Full Text] [Related]
29. Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice.
Hoogaars WM; Mouisel E; Pasternack A; Hulmi JJ; Relizani K; Schuelke M; Schirwis E; Garcia L; Ritvos O; Ferry A; 't Hoen PA; Amthor H
Hum Gene Ther; 2012 Dec; 23(12):1269-79. PubMed ID: 22894762
[TBL] [Abstract][Full Text] [Related]
30. Co-Administration of Myostatin-Targeting siRNA and ActRIIB-Fc Fusion Protein Increases Masseter Muscle Mass and Fiber Size.
Bayarsaikhan O; Kawai N; Mori H; Kinouchi N; Nikawa T; Tanaka E
J Nutr Sci Vitaminol (Tokyo); 2017; 63(4):244-248. PubMed ID: 28978871
[TBL] [Abstract][Full Text] [Related]
31. Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist.
Toledo M; Busquets S; Penna F; Zhou X; Marmonti E; Betancourt A; Massa D; López-Soriano FJ; Han HQ; Argilés JM
Int J Cancer; 2016 Apr; 138(8):2021-9. PubMed ID: 26595367
[TBL] [Abstract][Full Text] [Related]
32. Regulation of body mass growth through activin type IIB receptor in teleost fish.
Carpio Y; Acosta J; Morales R; Santisteban Y; Sanchéz A; Estrada MP
Gen Comp Endocrinol; 2009 Jan; 160(2):158-67. PubMed ID: 19056390
[TBL] [Abstract][Full Text] [Related]
33. Novel ActRIIB ligand trap increases muscle mass and improves bone geometry in a mouse model of severe osteogenesis imperfecta.
Tauer JT; Rauch F
Bone; 2019 Nov; 128():115036. PubMed ID: 31419601
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of activin A receptor signalling attenuates age-related pathological cardiac remodelling.
Clavere NG; Alqallaf A; Rostron KA; Parnell A; Mitchell R; Patel K; Boateng SY
Dis Model Mech; 2022 May; 15(5):. PubMed ID: 35380160
[TBL] [Abstract][Full Text] [Related]
35. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
36. Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunction.
Pistilli EE; Bogdanovich S; Mosqueira M; Lachey J; Seehra J; Khurana TS
Am J Physiol Regul Integr Comp Physiol; 2010 Jan; 298(1):R96-R103. PubMed ID: 19864340
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice.
Sumner CJ; Wee CD; Warsing LC; Choe DW; Ng AS; Lutz C; Wagner KR
Hum Mol Genet; 2009 Sep; 18(17):3145-52. PubMed ID: 19477958
[TBL] [Abstract][Full Text] [Related]
38. Emerging role of myostatin and its inhibition in the setting of chronic kidney disease.
Verzola D; Barisione C; Picciotto D; Garibotto G; Koppe L
Kidney Int; 2019 Mar; 95(3):506-517. PubMed ID: 30598193
[TBL] [Abstract][Full Text] [Related]
39. Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy.
Morine KJ; Bish LT; Selsby JT; Gazzara JA; Pendrak K; Sleeper MM; Barton ER; Lee SJ; Sweeney HL
Muscle Nerve; 2010 Nov; 42(5):722-30. PubMed ID: 20730876
[TBL] [Abstract][Full Text] [Related]
40. Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy.
Pistilli EE; Bogdanovich S; Goncalves MD; Ahima RS; Lachey J; Seehra J; Khurana T
Am J Pathol; 2011 Mar; 178(3):1287-97. PubMed ID: 21356379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
